OREANDA-NEWS  In Russia, the availability of devices of the Irish-American company Medtronic for the treatment of diabetes has decreased due to import disruptions due to US sanctions. This was announced by Natalia Mokrysheva, director of the National Medical Research Center of Hematology (NMIC of Endocrinology), writes Kommersant.

Medtronic manufactures products for continuous glucose monitoring (HMG). Back in May 2023, some components of the monitoring system were included in the American list of dual-use products, which made it difficult to import them to Russia.

In order to supply dual-use products manufactured by Medtronic, you need to obtain a separate license. In turn, the Irish-American company pointed to continuous work to ensure stable supplies for diabetic patients to the Russian market.

Against the background of import difficulties, the Ministry of Health is looking for alternative products. Now the agency is checking devices from China, which, according to Mokrysheva, "do not all meet our requirements for patients."

Earlier it became known that German medicines for heart attack and stroke "Mikardis" and "Mikardis-plus" from the pharmaceutical company Boehringer Ingelheim stopped supplying to Russia — deliveries stopped in the summer of 2022. Roszdravnadzor, assessing the consequences of the termination of the supply of the German drug, said that this would not affect the availability of medicines with the active substance telmisartan in the country.